India clears world's first dengue vaccine. Here's when you can actually get it

For crores of people in India, where the disease returns every monsoon, the vaccine offers prevention of dengue, and not just treatment. Pics/iStock

After decades of relying on mosquito control, public awareness campaigns, and supportive treatment to combat dengue, India has taken a significant step in its fight against the disease. The Drug Controller General of India has approved the manufacture of QDENGA, the world's first widely approved dengue vaccine, offering hope that the country may finally have an additional weapon against one of its fastest-growing seasonal health threats.

The approval has allowed a Hyderabad-based pharmaceutical company to manufacture QDENGA, a vaccine originally developed by a Japanese pharmaceutical firm. While the development has been welcomed by public health experts, they caution that the approval marks only the beginning of a lengthy process before the vaccine actually reaches the public.

Experts observe that introducing a vaccine to a country as large and diverse as India involves multiple layers of planning. "Apart from scaling up manufacturing, authorities will need to decide pricing, identify eligible beneficiaries, develop procurement strategies, train healthcare workers and determine whether the vaccine should become part of public immunisation programmes," said Dr Shailesh Mohite, dean, Nair Hospital.

Already approved for use in 43 countries, QDENGA has been administered to approximately 37 million people globally since its rollout in 2022. The vaccine has been introduced in several national immunisation programmes overseas, where health authorities continue to monitor its effectiveness and safety. However, Indian experts say expectations need to be tempered.

"At present, we have received approval only to manufacture it. Production and distribution, costing and procurement at state government levels will take at least a year. As we aren't importing it yet from Japan, even the private hospitals won't have it any time soon. So, if anyone thinks they can go and get the vaccine immediately, that won't be possible at least until next year's monsoon," said Dr Tushar Palave, vice dean of Cama and Albess Hospital.

The timeline is particularly relevant as India enters another dengue season. The disease has become an annual public health challenge, with hospitals across major cities witnessing a surge in admissions during the monsoon months when stagnant water creates ideal breeding conditions for the Aedes mosquitoes.
As per data from the WHO, one-third of all cases across the world are recorded in India. Furthermore, the National Centre for Vector Borne Diseases Control has reported 6927 dengue cases and 10 deaths so far in 2026.

Public health specialists believe that while the vaccine could eventually reduce the severity of the disease and hospitalisations, it is unlikely that it will help in complete prevention any time soon. "This vaccine is just like the ones developed during Covid-19. This is an immunity booster vaccine and not something like a polio vaccine given to infants and children. This two-dose, live-attenuated, tetravalent vaccine boosts a person's immunity against dengue. Thus, this does not mean that if one takes both doses of vaccine, he/she/they will never catch dengue.

However, taking the vaccine reduces one's vulnerability to catching the disease and in case even if one gets dengue despite taking the virus, the intensity remains suppressed, thus reducing the need to get hospitalised and eventually lowering the death rate," explained Dr Palave.

Daksha Shah, executive health officer at BMC, says, "QDENGA is a promising addition to our dengue prevention strategy, particularly in urban settings where high population density and favourable mosquito breeding conditions increase the risk of transmission. However, the vaccine should not be viewed as a standalone solution. Its effectiveness is maximised when combined with strong vector control measures, early diagnosis, public awareness and community participation. The primary public health benefit of vaccination lies in reducing severe dengue, hospitalisations and deaths, thereby easing the burden on healthcare facilities during peak transmission seasons."

For now, though, the prospect of preventing dengue - and not just treating it - appears to be within reach.

The dengue-carrying Aedes aegypti mosquito has long been Mumbai's monsoon menace

1/3
Of all dengue cases in the world are recorded in India

6927
No. of dengue cases in India in 2026

10
No. of dengue deaths in India in 2026

1st
Tamil Nadu has most dengue cases (2873)

2nd
Maharashtra has the second-highest no. (786)

43
No. of countries where QDENGA usage is approved

37 million
No. of people worldwide who have benefited from it 2022

'Sources: WHO, National Centre for Vector Borne Diseases Control

All about QDENGA

. Effective on all four types of dengue
. Two-dose vaccine; each is 0.5 ml, with 3 months' gap in between
. Anyone between 4 and 60 can get it
. Can be given to those with comorbidities
. Dengue test is not required for the vaccine